Curebase Celebrates Year of Growth, Organizational Maturity

DCT platform firm expands enterprise, provides govt expertise

SAN FRANCISCO, Jan. 4, 2023 /PRNewswire/ — Curebase, an organization dedicated to democratizing entry to medical research, capped off a profitable 2022 with continued progress, maturity, and growth of its footprint within the decentralized medical trials (DCT) market.

Curebase was based in 2017, by CEO Tom Lemberg, to make participation in medical trials out there to any affected person, regardless of location. Lemberg, a recipient of the 2022 Forbes 30 Under 30 management award, believes in increasing affected person entry and variety in medical research.

Among the main highlights, accomplishments, and milestones for Curebase in 2022 are:

  • Launched 21 new research
  • Enrolled 5,824 sufferers in medical trials
  • Enabled 10,643 website visits
  • Reached 4,111 zip codes for affected person prescreening
  • Released the Curebase Universal Mobile App
  • Launched plug-and-play software program and full trial providers providing for diagnostic research
  • Celebrated the Company’s fifth anniversary in November

Advisory and govt expertise

The firm strengthened its advisory board by naming a number of {industry} veterans to the panel. In February, Curebase added Dr. Aaron Kamauu, an industry-leading knowledgeable in real-world information (RWD), and Dr. Amir Lahav, an innovator in synthetic intelligence/machine studying digital biomarker growth for neurodegenerative ailments. Three months later, the corporate named to the board Lars-Olof “Lollo” Eriksson, a four-decade veteran of the pharmaceutical and medical analysis industries.

Curebase additionally stuffed out its govt ranks in 2022, hiring skilled {industry} luminaries to function the VPs of 5 important divisions inside the firm: medical operations, engineering, folks, finance, and authorized.

Series B funding

The firm introduced, in May, $40 million in Series B funding to proceed the growth of its DCT software program and providers platform. The new funding spherical included a strategic funding by world biopharmaceutical firm Gilead Sciences to deepen its partnership with Curebase within the implementation of DCTs and hybrid website capabilities in interventional trials.

Industry management

Continuing its position as a thought chief within the medical trials house, Curebase collaborated with {industry} companions and specialists on a number of informative and insightful publications in 2022.

The firm launched a paper in December in partnership with the Digital Therapeutics Alliance (DTA) that gives a fit-for-purpose proof customary for the regulatory, reimbursement, and medical acceptance of digital therapeutics (DTx) merchandise.

In October, the Association of Clinical Research Professionals (ACRP) revealed an article co-authored by Curebase Vice President of Clinical Trial Innovation Jane Myles and Krystyna Kowalczyk, CEO of medical analysis group Oncobay Clinical, on how DCTs can rework oncology remedy analysis. This was along with other notable thought articles and webinars from Myles specializing in patient-centricity, affected person and website expertise, and FDA steering within the medical trials house.

Industry partnerships

Curebase continued constructing and deepening associate relationships with firms comparable to BEKhealth, CoBTek, Portamedic, and Redenlab to develop affected person entry, information seize talents, and streamline recruitment efforts.

Looking forward

As the brand new 12 months begins, Curebase will proceed to develop its enterprise, with a deal with diagnostics and digital therapeutics research, that are each well-suited and in demand for decentralization.

“We made nice progress in additional validating our platform and skilled robust progress in our enterprise over the previous 12 months,” stated Lemberg. “This is a tribute to our data-driven, but versatile technique, our devoted staff members, and the facility of our mission to remodel medical trials. Curebase appears to be like ahead to extra success in 2023 as we allow an rising quantity of research and assist streamline the designing, recruiting, and execution of these trials.”

About Curebase

At Curebase, our mission is to convey high quality medical improvements to sufferers quicker and enhance human well-being via extra environment friendly medical research. We are proving that medical analysis will be radically accelerated if we empower physicians all over the place to enroll sufferers within the communities the place they reside. By making use of cutting-edge medical software program and distant research administration strategies to the issue, we’re reinventing medical trials and analysis from the bottom up.

Media Contact:
Shawn Malloy
[email protected]

SOURCE Curebase

Related Posts